Research / Stocks / MBOT MBOT Nasdaq CIK 0000883975
Microbot Medical Inc. · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 8-K · Aug 11, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT Microbot Medical Inc.'s latest supported as-filed period reports revenue of $241,000 . Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Capex intensity RAW Current state valid · history insufficient
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 58.92% · OPTIONAL
Operating cash generation RAW Current state valid · history insufficient
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -2070.12% · OPTIONAL
Inventory pressure RAW Current state valid · history insufficient
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 1206.22% · OPTIONAL
Gross margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.gross_margin
Raw value -266.80% · CORE
Operating margin RAW Current state valid · history insufficient
Method Level · gp.fundamentals.operating_margin
Raw value -2567.63% · CORE
R&D intensity RAW Current state valid · history insufficient
Method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 772.20% · OPTIONAL
SBC intensity RAW Current state valid · history insufficient
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Governance Evidence 3 evidence-backed dimensions Filing Amendments None Detected Auditor Changes None Detected Sbc Intensity Observed [email protected] · 2 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Profitability
MBOT -2567.6
Peer median -5.8
Peer percentile 5th 83 valid peers · 94% coverage · -74.4 robust σ Cash Generation
MBOT -2070.1
Peer median -6.1
Peer percentile 5th 81 valid peers · 92% coverage · -64.9 robust σ R And D Intensity
MBOT 772.2
Peer median 12.0
Peer percentile 93th 68 valid peers · 77% coverage · +55.9 robust σ Inventory Pressure
MBOT 1206.2
Peer median 72.0
Peer percentile 99th 79 valid peers · 90% coverage · +37.2 robust σ Sbc Intensity
MBOT 179.7
Peer median 5.6
Peer percentile 95th 81 valid peers · 92% coverage · +26.3 robust σ Margin
MBOT -266.8
Peer median 64.6
Peer percentile 0th 76 valid peers · 86% coverage · -20.4 robust σ Open group breadth → Divergence is context, not positive or negative. Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001493152-26-037009 4 governed changes · top 4 shown
01
HIGH IMPORTANCE Cash 25TH HISTORICAL PCTL · N=4
Cash & equivalents decreased 22.8% Cash & equivalents changed -22.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Why this ranks here · [email protected] $4.1M → $3.2M Comparable → current
02
HIGH IMPORTANCE Net Income 100TH HISTORICAL PCTL · N=3
Net income decreased 60.8% Net income changed -60.8% from the comparable as-filed period.
Why this ranks here · [email protected] -$3.5M → -$5.6M Comparable → current
03
HIGH IMPORTANCE Operating Income 100TH HISTORICAL PCTL · N=4
Operating income decreased 66.2% Operating income changed -66.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Why this ranks here · [email protected] -$3.7M → -$6.2M Comparable → current
04
MEDIUM IMPORTANCE R And D 50TH HISTORICAL PCTL · N=4
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 58.92% -42.7% ↓ Capital expenditure $142,000 +31.5% ↑ Cash & equivalents $3.2M +0.0% ↑ Free-cash-flow proxy -$5.1M +0.6% ↑ Gross margin -266.80% +0.0% ↑ Interest expense $237,000 +0.0% ↑ Interest income $561,000 -13.6% ↓ Inventory $2.9M +28.8% ↑
ACTIVE TRACE Revenue MBOT · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 58.92% -42.7% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $142,000 +31.5% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $3.2M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 -$5.1M +0.6% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 -266.80% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense FY / 2017-12-31 $237,000 +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest income Q2 / 2026-06-30 $561,000 -13.6% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $2.9M +28.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 -$5.6M -53.3% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 -$5.0M +1.3% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 -2567.63% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q2 / 2026-06-30 $1.9M +43.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
8-K Aug 11, 2026 Period Aug 11, 2026 0001493152-26-037031SEC ↗ 10-Q Aug 11, 2026 Period Jun 30, 2026 0001493152-26-037009SEC ↗ 8-K Aug 7, 2026 Period Aug 6, 2026 0001493152-26-036600SEC ↗ 8-K Jul 21, 2026 Period Jul 21, 2026 0001493152-26-034014SEC ↗ 8-K Jul 7, 2026 Period Jul 7, 2026 0001493152-26-032260SEC ↗ 8-K Jun 30, 2026 Period Jun 30, 2026 0001493152-26-031205SEC ↗ 8-K Jun 25, 2026 Period Jun 25, 2026 0001493152-26-030038SEC ↗ 8-K Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗